Zinc(II)—The Overlooked Éminence Grise of Chloroquine’s Fight against COVID-19? Hecel, Aleksandra Domínguez Martín, Alicia COVID-19 SARS-CoV-2 2019-nCoV Zn(II) ionophores Chloroquine Hydroxychloroquine The authors would like to thank Agnieszka Michalczuk for providing us with her artistic vision of SARS-CoV-2. Zn(II) is an inhibitor of SARS-CoV-2′s RNA-dependent RNA polymerase, and chloroquine and hydroxychloroquine are Zn(II) ionophores–this statement gives a curious mind a lot to think about. We show results of the first clinical trials on chloroquine (CQ) and hydroxychloroquine (HCQ) in the treatment of COVID-19, as well as earlier reports on the anticoronaviral properties of these two compounds and of Zn(II) itself. Other FDA-approved Zn(II) ionophores are given a decent amount of attention and are thought of as possible COVID-19 therapeutics. 2020-11-12T11:34:32Z 2020-11-12T11:34:32Z 2020-09-01 journal article Hecel, A.; Ostrowska, M.; Stokowa-Sołtys, K.; Wątły, J.; Dudek, D.; Miller, A.; Potocki, S.; Matera-Witkiewicz, A.; Dominguez-Martin, A.; Kozłowski, H.; Rowińska-Żyrek, M. Zinc(II)—The Overlooked Éminence Grise of Chloroquine’s Fight against COVID-19? Pharmaceuticals 2020, 13, 228. [doi:10.3390/ph13090228] http://hdl.handle.net/10481/64223 10.3390/ph13090228 eng http://creativecommons.org/licenses/by/3.0/es/ open access Atribución 3.0 España MDPI